Physician

Anna Kovalszki, M.D.

According to 2025 Medicare claims, Anna Kovalszki, M.D. (NPI: 1477587137) practices allergy/immunology in the Ann Arbor, MI market, with the plurality of this provider's patient population coming from Washtenaw, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1700816881; TIN: 386006309) and primary practice location at 48103-6201. Kovalszki is affiliated with the POM ACO (ACO ID: A1297), participating under the MSSP model.

Kovalszki's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 102 traditional Medicare patients, billed 187 HCPCS/CPT codes, and received $9,724 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 673 prescription claims across 103 beneficiaries totaling $1,305,709 in drug costs, led by Orladeyo (Berotralstat Hydrochloride). DME data shows 159 claims. Open Payments data shows 2 records totaling $27,467. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $100,485 to $9,724. In contrast, Part D prescription costs have moved sharply higher in recent years, from $43,598 to $1,305,709. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $785 to $2,447.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	203	5,726	$100,485
2016	185	3,043	$44,151
2017	120	479	$11,546
2018	161	564	$14,395
2019	147	394	$15,066
2020	121	179	$11,029
2021	133	250	$15,087
2022	127	184	$12,390
2023	133	172	$11,481
2024	102	187	$9,724

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	88	333	$43,598
2016	81	316	$136,544
2017	52	177	$119,769
2018	73	311	$177,901
2019	76	306	$191,103
2020	78	331	$274,083
2021	94	425	$338,039
2022	79	399	$374,742
2023	84	460	$546,360
2024	103	673	$1,305,709

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	36	$61,570
2016	N/R	69	$121,831
2017	N/R	36	$48,073
2018	N/R	N/R	N/R
2019	N/R	38	$2,454
2020	N/R	158	$137,880
2021	N/R	118	$153,878
2022	N/R	147	$231,238
2023	N/R	169	$336,334
2024	N/R	159	$217,835

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	24	24	$87
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	70	80	$66
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	12	12	$46
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	22	24	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Orladeyo	Berotralstat Hydrochloride	13	364	$573,009
Cuvitru	Immun Glob G(Igg)/Gly/Iga Ov50	28	784	$165,885
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	43	840	$138,496
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	32	854	$115,995
Xolair	Omalizumab	24	672	$73,475

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	26	$116,020
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	36	$99,433
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	38	$1,943
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	59	$440

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$84	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$27,383	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anna Kovalszki, M.D.?

Tedicare shows public-source Medicare data for Anna Kovalszki, M.D. (NPI 1477587137), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anna Kovalszki, M.D. have ACO affiliation data?

Anna Kovalszki, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297).

What billing organization is linked to Anna Kovalszki, M.D.?

Anna Kovalszki, M.D. is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1700816881) in the available physician profile data.

Does Anna Kovalszki, M.D. have Open Payments data?

Anna Kovalszki, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.